Nutrition 21, Inc. Announces Successful Transition to OTC Bulletin Board

PURCHASE, N.Y. , Oct. 23 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. (OTC
Bulletin Board: NXXI), the developer and marketer of nutritional supplements
under the Iceland Health®, Chromax® and Diabetes Essentials® brands that help
consumers manage blood sugar levels, improve cardiovascular health, enhance
memory and reduce chronic joint pain, announced today that on October 20, 2009
the listing of its common stock on the NASDAQ Capital Market was successfully
transferred to listing on the OTC Bulletin Board under the symbol NXXI.OB.

About Nutrition 21
Nutrition 21, Inc., headquartered in Purchase, NY, is a nutritional bioscience
company and the maker of chromium picolinate-based and omega-3 fish oil-based
supplements with health benefits substantiated by clinical research. Nutrition
21 holds more than 30 patents for nutrition products and uses. Nutrition 21's
portfolio of health and wellness products include: Iceland Health Chromax,
Iceland Health Advanced Memory Formula(TM), Iceland Health Omega-3 Fish Oil,
Iceland Health Joint Relief, and Diabetes Essentials® The company also
manufactures private label supplements and ingredients for third parties.
Nutrition 21 distributes its products nationally through more than 30,000
major food, drug and super center stores throughout the United States and
internationally. For more information please visit http://www.nutrition21.com.

Safe Harbor Provision
This press release may contain certain forward-looking statements. The words
"believe," "expect," "anticipate" and other similar expressions generally
identify forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of their
dates. These forward-looking statements are based largely on the company's
current expectations and are subject to a number of risks and uncertainties,
including without limitation: the effect of the expiration of patents;
regulatory issues; uncertainty in the outcomes of clinical trials; changes in
external market factors; changes in the company's business or growth strategy
or an inability to execute its strategy due to changes in its industry or the
economy generally; the emergence of new or growing competitors; various other
competitive factors; and other risks and uncertainties indicated from time to
time in the company's filings with the Securities and Exchange Commission,
including its Form 10-K for the year ended June 30, 2009. Actual results could
differ materially from the results referred to in the forward-looking
statements. In light of these risks and uncertainties, there can be no
assurance that the results referred to in the forward-looking statements
contained in this press release will in fact occur. Additionally, the company
makes no commitment to disclose any revisions to forward-looking statements,
or any facts, events or circumstances after the date hereof that may bear upon
forward-looking statements.

Contact:
Nutrition 21, Inc. Lytham Partners, LLC
Alan Kirschbaum Joe Diaz
(914) 701-4500 (602) 889-9700

SOURCE Nutrition 21, Inc.

Alan Kirschbaum of Nutrition 21, Inc., +1-914-701-4500; or Joe Diaz of Lytham
Partners, LLC, +1-602-889-9700, for Nutrition 21, Inc.